Can Anti-Diarrhea pills tame a promising cancer Drug's side effects?
NCT ID NCT07426822
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether giving preventive medications (loperamide for diarrhea and cetirizine for rash) can reduce common side effects of the cancer drug capivasertib when combined with fulvestrant. About 108 adults with HR+/HER2- metastatic breast cancer will participate. The goal is to improve quality of life and help patients stay on treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Capivasertib, fulvestrant, loperamide, cetirizine
What this could lead to
If successful, this could show that simple preventive drugs can make a standard breast cancer treatment much more tolerable, helping patients stay on therapy longer.
What could go wrong
This is a small, early-phase trial focused on side effects, not on curing cancer. The preventive strategies may not work as hoped, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HR+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
New Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact